The European Medicines Agency (EMA) aims to decide in early October whether to endorse a third dose of the Pfizer-BioNTech COVID-19 vaccine to be given half a year after the initial two-shot course, saying breakthrough infections added some urgency to its review.
“The outcome of this evaluation is expected in early October, unless supplementary information is needed,” EMA’s head of vaccines strategy, Marco Cavaleri, told a press briefing on Thursday.
